预约演示
更新于：2026-04-04
Albenatide
艾本那肽
更新于：2026-04-04
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 3958
来源: *****
Sequence Code 37437
来源: *****
关联
12
项与 艾本那肽 相关的临床试验NCT05990374
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
CTR20222496
评价健康受试者皮下注射CJC-1134-PC注射液分别与二甲双胍、阿托伐他汀、华法林药物-药物相互作用的临床研究
NCT07057271
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
100 项与 艾本那肽 相关的临床结果
登录后查看更多信息
100 项与 艾本那肽 相关的转化医学
登录后查看更多信息
100 项与 艾本那肽 相关的专利（医药）
登录后查看更多信息
3
项与 艾本那肽 相关的文献（医药）2021-12-02EXPERT OPINION ON INVESTIGATIONAL DRUGS
Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects
Article
作者: Yang, Lizhi ; Yao, Zhiwen ; Ding, Yanhua ; Wu, Min ; Xie, Qiang ; Liu, Xiping ; Zhang, Hong ; Li, Cuiyun ; Zhu, Xiaoxue
BACKGROUND:
Glucagon-like peptide-1 (GLP-1) mimetics are widely used for treating type 2 diabetes (T2D) with pleiotropic effects on heart and kidneys. The safety/tolerability and pharmacokinetics/pharmacodynamics ((PK/PD) of CJC-1134-PC (a long-acting GLP-1) were investigated in Chinese.
METHOD:
Two randomized, double-blind, placebo-controlled phase I studies were conducted. Study A: 30 healthy subjects received (subcutaneously injected) a single dose (2 mg) or titrate doses (2 + 3 and 2 + 3 + 4 mg at weekly intervals) of CJC-1134-PC. Study B: 49 T2D subjects received 10 weekly doses (1, 2, 3, and 4 mg).
RESULT:
CJC-1134-PC was well tolerated with gastrointestinal (GI) side effects. Higher doses increased the adverse events risk. CJC-1134-PC was steadily absorbed, with maximum plasma concentrations(Cmax) occurring at 36-72 h and 48 h after administration in healthy and T2D subjects, respectively. The steady-state exposures in T2D subjects increased more than the dose-proportionality(1-3 mg). The mean t1/2 ranged from 111.6 to 127.6 h. After four- five weeks of targeting doses, steady state was reached in T2D subjects with apparent accumulation effect. At week 11 for T2D subjects, HbA1c mean baseline change was significantly different than that of the placebo, and the fasting plasma glucose (FPG) was not significantly altered.
CONCLUSION:
The safety and PK/PD profiles of weekly CJC-1134-PC doses support Phase II studies with guidance on optimal-dose selection. Clinical trial registration: ChiCTR-IPC-15007190.
2010-04-01Current diabetes reports2区 · 医学
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
2区 · 医学
Review
作者: Christensen, Mikkel ; Knop, Filip K.
Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.
2008-04-01Gastroenterology1区 · 医学
An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis
1区 · 医学
Article
作者: Daniel J. Drucker ; Laurie L. Baggio ; Xiemin Cao ; Qingling Huang
BACKGROUND & AIMS:
Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis through multiple mechanisms including direct actions on the endocrine pancreas and indirect activation of central nervous system circuits regulating gastric emptying, satiety, and body weight. Because native GLP-1 is rapidly degraded, there is considerable interest in development of more potent GLP-1 receptor (GLP-1R) agonists with sustained activity; however, the extent to which much larger GLP-1R agonists will mimic some or all of the actions of smaller peptides remains uncertain.
METHODS:
We studied the actions of CJC-1134-PC, a recombinant human serum albumin-exendin-4 conjugated protein, at the GLP-1R using heterologous cells expressing the GLP-1R in vitro and both wild-type and Glp1r(-/-) mice in vivo.
RESULTS:
CJC-1134-PC activated GLP-1R-dependent signaling in baby hamster kidney-GLP-1R cells and acutely lowered blood glucose in wild-type but not in Glp1r(-/-) mice. Moreover, acute administration of CJC-1134-PC rapidly activated c-Fos expression in multiple regions of the central nervous system, acutely inhibited gastric emptying, and produced sustained inhibition of food intake in a GLP-1R-dependent manner. Furthermore, chronic daily treatment of high-fat diet-fed wild-type mice with CJC-1134-PC for 4 weeks led to improved glucose tolerance, increased levels of glucose-stimulated insulin, decreased HbA1c, and weight loss associated with decreased hepatic triglyceride content.
CONCLUSIONS:
These findings illustrate that a high-molecular-weight exendin-4-albumin conjugate retains the ability to mimic a full spectrum of GLP-1R-dependent actions, including activation of central nervous system circuits regulating gastric emptying, food intake, and body weight.
100 项与 艾本那肽 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 申请上市 | 中国 | 2024-04-25 | |
| 肥胖 | 临床申请批准 | 中国 | 2025-06-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 73 | (Arm 1 - Weekly CJC-1134-PC) | 願範觸築觸獵齋遞齋觸(醖願艱衊醖製構範願壓) = 廠餘鏇積衊鑰鏇觸夢顧 膚顧夢衊齋簾鹹鹹繭壓 (製齋醖襯廠淵觸餘築鑰, 0.597) 更多 | - | 2017-07-19 | ||
(Arm 2 - Weekly CJC-1134-PC) | 願範觸築觸獵齋遞齋觸(醖願艱衊醖製構範願壓) = 繭鑰積願淵繭獵艱蓋選 膚顧夢衊齋簾鹹鹹繭壓 (製齋醖襯廠淵觸餘築鑰, 0.627) 更多 | ||||||
临床2期 | 122 | (1.5 mg CJC-1134-PC) | 襯獵繭構廠壓網築繭艱(糧憲鑰壓繭鬱鹽顧鬱網) = 選獵簾積鏇蓋醖遞簾艱 獵淵夢襯簾窪構鏇齋構 (鏇壓醖夢壓範鹽構糧壓, 0.883) 更多 | - | 2017-06-02 | ||
(1.5 or 2.0 mg CJC-1134-PC) | 襯獵繭構廠壓網築繭艱(糧憲鑰壓繭鬱鹽顧鬱網) = 淵觸鹹築夢獵繭顧憲製 獵淵夢襯簾窪構鏇齋構 (鏇壓醖夢壓範鹽構糧壓, 0.827) 更多 | ||||||
临床2期 | 90 | (1.5 mg CJC-1134-PC) | 鏇廠獵衊鹹構築積餘壓(壓廠膚遞遞壓餘壓選憲) = 選糧衊壓鹹獵願夢範獵 簾醖夢積淵鹹顧齋構壓 (遞憲窪網顧窪膚簾襯遞, 1.226) 更多 | - | 2017-06-02 | ||
(1.5 mg or 2.0 mg CJC-1134-PC) | 鏇廠獵衊鹹構築積餘壓(壓廠膚遞遞壓餘壓選憲) = 淵蓋鏇獵鏇壓鏇願窪襯 簾醖夢積淵鹹顧齋構壓 (遞憲窪網顧窪膚簾襯遞, 0.672) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用